Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71:7–33.

PubMed  Google Scholar 

Hackl C, Neumann P, Gerken M, Loss M, Klinkhammer-Schalke M, Schlitt HJ. Treatment of colorectal liver metastases in Germany: a ten-year population-based analysis of 5772 cases of primary colorectal adenocarcinoma. BMC Cancer. 2014;14:810.

PubMed  PubMed Central  Google Scholar 

Manfredi S, Lepage C, Hatem C, Coatmeur O, Faivre J, Bouvier A-M. Epidemiology and management of liver metastases from colorectal cancer. Ann Surg. 2006;244:254–9.

PubMed  PubMed Central  Google Scholar 

Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet. 2019;393:2051–8.

PubMed  PubMed Central  Google Scholar 

Aloia TA, Vauthey J-N, Loyer EM, Ribero D, Pawlik TM, Wei SH, Curley SA, Zorzi D, Abdalla EK. Solitary colorectal liver metastasis: resection determines outcome. Arch Surg. 2006;141:460–6 (discussion 466-467).

PubMed  Google Scholar 

Morris EJA, Forman D, Thomas JD, Quirke P, Taylor EF, Fairley L, Cottier B, Poston G. Surgical management and outcomes of colorectal cancer liver metastases. Br J Surg. 2010;97:1110–8.

CAS  PubMed  Google Scholar 

Van Cutsem E, Nordlinger B, Adam R, Köhne C-H, Pozzo C, Poston G, Ychou M, Rougier P, European Colorectal Metastases Treatment Group. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer. 2006;42:2212–21.

PubMed  Google Scholar 

Ye L-C, Liu T-S, Ren L, et al. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases. J Clin Oncol. 2013;31:1931–8.

CAS  PubMed  Google Scholar 

Folprecht G, Gruenberger T, Bechstein WO, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol. 2010;11:38–47.

CAS  PubMed  Google Scholar 

Chang BK, Timmerman RD. Stereotactic body radiation therapy: a comprehensive review. Am J Clin Oncol. 2007;30:637–44.

PubMed  Google Scholar 

Mahadevan A, Blanck O, Lanciano R, Peddada A, Sundararaman S, D’Ambrosio D, Sharma S, Perry D, Kolker J, Davis J. Stereotactic body radiotherapy (SBRT) for liver metastasis – clinical outcomes from the international multi-institutional RSSearch® Patient Registry. Radiat Oncol. 2018;13:1–11.

Google Scholar 

Kok END, Jansen EPM, Heeres BC, Kok NFM, Janssen T, van Werkhoven E, Sanders FRK, Ruers TJM, Nowee ME, Kuhlmann KFD. High versus low dose stereotactic body radiation therapy for hepatic metastases. Clin Transl Radiat Oncol. 2019;20:45–50.

PubMed  PubMed Central  Google Scholar 

Rusthoven KE, Kavanagh BD, Cardenes H, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. JCO. 2009;27:1572–8.

Google Scholar 

Lee MT, Kim JJ, Dinniwell R, et al. Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol. 2009;27:1585–91.

PubMed  Google Scholar 

Rule W, Timmerman R, Tong L, Abdulrahman R, Meyer J, Boike T, Schwarz RE, Weatherall P, Chinsoo Cho L. Phase I dose-escalation study of stereotactic body radiotherapy in patients with hepatic metastases. Ann Surg Oncol. 2011;18:1081–7.

PubMed  Google Scholar 

Goodman KA, Wiegner EA, Maturen KE, Zhang Z, Mo Q, Yang G, Gibbs IC, Fisher GA, Koong AC. Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies. Int J Radiat Oncol Biol Phys. 2010;78:486–93.

PubMed  Google Scholar 

Herfarth KK, Debus J, Wannenmacher M. Stereotactic radiation therapy of liver metastases: update of the initial phase-I/II trial. Front Radiat Ther Oncol. 2004;38:100–5.

PubMed  Google Scholar 

Wulf J, Guckenberger M, Haedinger U, Oppitz U, Mueller G, Baier K, Flentje M. Stereotactic radiotherapy of primary liver cancer and hepatic metastases. Acta Oncol. 2006;45:838–47.

PubMed  Google Scholar 

Hoyer M, Roed H, Traberg Hansen A, Ohlhuis L, Petersen J, Nellemann H, Kiil Berthelsen A, Grau C, Aage Engelholm S, Von der Maase H. Phase II study on stereotactic body radiotherapy of colorectal metastases. Acta Oncol. 2006;45:823–30.

PubMed  Google Scholar 

van der Pool AEM, Méndez Romero A, Wunderink W, Heijmen BJ, Levendag PC, Verhoef C, Ijzermans JNM. Stereotactic body radiation therapy for colorectal liver metastases. Br J Surg. 2010;97:377–82.

PubMed  Google Scholar 

Chang DT, Swaminath A, Kozak M, et al. Stereotactic body radiotherapy for colorectal liver metastases: a pooled analysis. Cancer. 2011;117:4060–9.

PubMed  Google Scholar 

Joo JH, Park J-H, Kim JC, et al. Local control outcomes using stereotactic body radiation therapy for liver metastases from colorectal cancer. Int J Radiat Oncol Biol Phys. 2017;99:876–883. CLM SBRT cohort study that showed LC benefit with BED >130 Gy. This study shows higher ablative radiation doses may lead to improved LC.

PubMed  Google Scholar 

Méndez Romero A, Schillemans W, van Os R, et al. The Dutch-Belgian Registry of stereotactic body radiation therapy for liver metastases: clinical outcomes of 515 patients and 668 metastases. Int J Radiat Oncol Biol Phys. 2021;109:1377–86.

PubMed  Google Scholar 

Clerici E, Comito T, Franzese C, et al. Role of stereotactic body radiation therapy in the treatment of liver metastases: clinical results and prognostic factors. Strahlenther Onkol. 2020;196:325–33.

PubMed  Google Scholar 

Andratschke N, Alheid H, Allgäuer M, et al. The SBRT database initiative of the German Society for Radiation Oncology (DEGRO): patterns of care and outcome analysis of stereotactic body radiotherapy (SBRT) for liver oligometastases in 474 patients with 623 metastases. BMC Cancer. 2018;18:283.

CAS  PubMed  PubMed Central  Google Scholar 

Franzese C, Comito T, Clerici E, et al. Liver metastases from colorectal cancer: propensity score-based comparison of stereotactic body radiation therapy vs. microwave ablation. J Cancer Res Clin Oncol. 2018;144:1777–83.

PubMed  Google Scholar 

Scorsetti M, Comito T, Tozzi A, et al. Final results of a phase II trial for stereotactic body radiation therapy for patients with inoperable liver metastases from colorectal cancer. J Cancer Res Clin Oncol. 2015;141:543–553. Phase II study of SBRT to CLM 75 Gy in 3 fractions (BED 262.5) that showed excellent rates of LC-CR 43% and 3 years LC 85%.

CAS  PubMed  Google Scholar 

Folkert MR, Meyer JJ, Aguilera TA, et al. Long-term results of a phase 1 dose-escalation trial and subsequent institutional experience of single-fraction stereotactic ablative radiation therapy for liver metastases. Int J Radiat Oncol Biol Phys. 2021;109:1387–1395. Phase I dose-escalation study 35 to 40 Gy in 1 fraction (BED >150) SBRT that showed high LC with low toxicity — 4-year LC 96% with no G3+ toxicities. This study demonstrates the feasibility, high LC, and low toxicity with single fraction ablative SBRT.

PubMed  Google Scholar 

McPartlin A, Swaminath A, Wang R, et al. Long-term outcomes of phase 1 and 2 studies of SBRT for hepatic colorectal metastases. Int J Radiat Oncol Biol Phys. 2017;99:388–95.

PubMed  Google Scholar 

Hong TS, Wo JY, Borger DR, et al. Phase II study of proton-based stereotactic body radiation therapy for liver metastases: importance of tumor genotype. JNCI J Natl Cancer Inst. 2017. https://doi.org/10.1093/jnci/djx031. Phase II proton SBRT study that showed higher LF in CLMs as well as those with KRAS and TP54 mutations. This study shows that CLMs have higher rates of LF and that certain genomic markers may help predict treatment response.

Article  PubMed  Google Scholar 

Creasy JM, Sadot E, Koerkamp BG, et al. Actual 10-year survival after hepatic resection of colorectal liver metastases: what factors preclude cure? Surgery. 2018;163:1238–44.

PubMed  Google Scholar 

Westover KD, Seco J, Adams JA, Lanuti M, Choi NC, Engelsman M, Willers H. Proton SBRT for medically inoperable stage I NSCLC. J Thorac Oncol. 2012;7:1021–5.

PubMed  PubMed Central  Google Scholar 

Toesca DAS, Koong AJ, von Eyben R, Koong AC, Chang DT. Stereotactic body radiation therapy for adrenal gland metastases: outcomes and toxicity. Adv Radiat Oncol. 2018;3:621–9.

PubMed  PubMed Central  Google Scholar 

Bush DA, Kayali Z, Grove R, Slater JD. The safety and efficacy of high-dose proton beam radiotherapy for hepatocellular carcinoma: a phase 2 prospective trial. Cancer. 2011;117:3053–9.

PubMed  Google Scholar 

Fukumitsu N, Sugahara S, Nakayama H, Fukuda K, Mizumoto M, Abei M, Shoda J, Thono E, Tsuboi K, Tokuuye K. A prospective study of hypofractionated proton beam therapy for patients with hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2009;74:831–6.

PubMed  Google Scholar 

Kawashima M, Furuse J, Nishio T, Konishi M, Ishii H, Kinoshita T, Nagase M, Nihei K, Ogino T. Phase II study of radiotherapy employing proton beam for hepatocellular carcinoma. J Clin Oncol. 2005;23:1839–46.

PubMed  Google Scholar 

Nakayama H, Sugahara S, Tokita M, Fukuda K, Mizumoto M, Abei M, Shoda J, Sakurai H, Tsuboi K, Tokuuye K. Proton beam therapy for hepatocellular carcinoma: the University of Tsukuba experience. Cancer. 2009;115:5499–506.

PubMed  Google Scholar 

Kang JI, Sufficool DC, Hsueh C-T, Wroe AJ, Patyal B, Reeves ME, Slater JD, Yang GY. A phase I trial of proton stereotactic body radiation therapy for liver metastases. J Gastrointest Oncol. 2019;10:112–7.

PubMed  PubMed Central  Google Scholar 

Petrelli F, Comito T, Barni S, Pancera G, Scorsetti M, Ghidini A, SBRT for CRC liver metastases. Stereotactic body radiotherapy for colorectal cancer liver metastases: a systematic review. Radiother Oncol. 2018;129:427–34.

PubMed  Google Scholar 

Lim YJ, Koh J, Kim S, et al. Chemoradiation-induced alteration of programmed death-ligand 1 and CD8+ tumor-infiltrating lymphocytes identified patients with poor prognosis in rectal cancer: a matched comparison analysis. Int J Radiat Oncol Biol Phys. 2017;99:1216–24.

PubMed  Google Scholar 

Twyman-Saint Victor C, Rech AJ, Maity A, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015;520:373–7.

CAS  PubMed  Google Scholar 

Schoenhals JE, Seyedin SN, Tang C, Cortez MA, Niknam S, Tsouko E, Chang JY, Hahn SM, Welsh JW. Preclinical rationale and clinical considerations for radiotherapy plus immunotherapy: going beyond local control. Cancer J. 2016;22:130–7.

CAS  PubMed  Google Scholar 

Monjazeb AM, Giobbie-Hurder A, Lako A, et al. A randomized trial of combined PD-L1 and CTLA-4 inhibition with targeted low-dose or hypofractionated radiation for patients with metastatic colorectal cancer. Clin Cancer Res. 2021;27:2470–2480. Phase II randomized study 8 Gy per day for 3 days vs. 2 Gy BID for 2 days combined with microsatellite stable CLM given in combination with anti-CTLA-4 and anti-PD-1 therapy. Although there was no improvement in extrahepatic disease, significant changes were noted in immune cell populations with treated tumor.

CAS  PubMed  PubMed Central  Google Scholar 

Ahmed KA, Fulp WJ, Berglund AE, Hoffe SE, Dilling TJ, Eschrich SA, Shridhar R, Torres-Roca JF. Differences between colon cancer primaries and metastases using a molecular assay for tumor radiation sensitivity suggest implications for potential oligometastatic SBRT patient selection. Int J Radiat Oncol Biol Phys. 2015;92:837–42.

PubMed  PubMed Central  Google Scholar 

Eccles C, Brock KK, Bissonnette J-P, Hawkins M, Dawson LA. Reproducibility of liver position using active breathing coordinator for liver cancer radiotherapy. Int J Radiat Oncol Biol Phys. 2006;64:751–9.

PubMed